<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791968</url>
  </required_header>
  <id_info>
    <org_study_id>CEIC-CHUT-969</org_study_id>
    <nct_id>NCT05791968</nct_id>
  </id_info>
  <brief_title>Blood Donation Could Improve Insulin Sensitivity</brief_title>
  <acronym>GLUCFER</acronym>
  <official_title>Effects of a Standard Blood Bank Donation on Insulin Sensitivity in Adults With Pre-diabetes and Abdominal Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Castilla-La Mancha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SESCAM Centro Regional de Transfusión Toledo-Guadalajara.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Castilla-La Mancha</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies in the literature suggest that people with obesity have an excess of stored iron.&#xD;
      There is possibly an inverse relationship between ferritin levels and the actions of insulin&#xD;
      on glycemic control. The reduction of stored iron by simply donating blood could result in&#xD;
      improvements in glycemic control in people with obesity and prediabetes. We propose, to&#xD;
      reduce ferritin levels through a standard donation of a unit of whole blood, and to measure&#xD;
      if it positively affects glycemic control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with pre-diabetes and abdominal obesity will be randomized to either a donation&#xD;
      group (DON) or a control group (CONT) in a double-blind fashion (RCT).&#xD;
&#xD;
      Insulin sensitivity during an oral glucose tolerance test (OGTT) and isotopically measured&#xD;
      rate of appearance of endogenous and exogenous glucose will be measured on 2 occasions.&#xD;
&#xD;
        1. Two weeks prior to DON/CONT&#xD;
&#xD;
        2. Two weeks after to DON/CONT&#xD;
&#xD;
      Indexes of the bodily iron stores will be measured after DON/CONT to evaluate if the primary&#xD;
      treatment was effective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2023</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, control group, trial (RCT)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>participants in the control group will have the standard blood bank donation venipuncture, but no blood will be withdrawn (sham donation).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity during an oral glucose tolerance test (OGTT)</measure>
    <time_frame>7 months</time_frame>
    <description>Measured with the calculations of Matsuda index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ferritin blood level</measure>
    <time_frame>7 months</time_frame>
    <description>iron stores index measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Turnover rate of endogenous and exogenous glucose</measure>
    <time_frame>7 months</time_frame>
    <description>Measured using isotopic tracers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carbohydrate oxidation</measure>
    <time_frame>7 months</time_frame>
    <description>Measured using indirect calorimetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Continuous glucose monitoring</measure>
    <time_frame>7 months</time_frame>
    <description>Interstitial blood glucose concentrations during 24-h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cuality of life</measure>
    <time_frame>7 months</time_frame>
    <description>Measured by SF 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid profile</measure>
    <time_frame>7 months</time_frame>
    <description>blood analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition (weight and body fat)</measure>
    <time_frame>7 months</time_frame>
    <description>TANITA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Ferritin</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Blood Donation</condition>
  <arm_group>
    <arm_group_label>DONATION GROUP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be measured before and after a standard blood bank donation (450 mL of whole blood withdrawal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will be measured before and after a sham blood donation (0 mL of whole blood withdrawal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Whole blood standard donation</intervention_name>
    <description>Effects of a standard whole blood donation on iron stores and insulin sensitivity.</description>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <arm_group_label>DONATION GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  have not donated in the last 3 months&#xD;
&#xD;
          -  IMC&gt;25&#xD;
&#xD;
          -  fasting blood glucose 100-125 mg/dL&#xD;
&#xD;
          -  glycosylated hemoglobin levels between 5.7-6.4%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  to not meet donor bank requirements&#xD;
&#xD;
          -  insulin treatment for diabetes&#xD;
&#xD;
          -  anemia&#xD;
&#xD;
          -  hereditary hemochromatosis&#xD;
&#xD;
          -  heart disease&#xD;
&#xD;
          -  familial hypertriglyceridemia or hypobetalipoproteinemia&#xD;
&#xD;
          -  any disease that requires medication that interferes with iron or glucose metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ricardo Mora-Rodriguez, PhD</last_name>
    <phone>925268800</phone>
    <email>ricardo.mora@uclm.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diego Mora-González, RN</last_name>
    <phone>675424515</phone>
    <email>diego.mora2@alu.uclm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Castilla-La Mancha (Exercise Physiology Lab)</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Mora-Rodriguez, PhD</last_name>
      <phone>92526800</phone>
      <phone_ext>5515</phone_ext>
      <email>ricardo.mora@uclm.es</email>
    </contact>
    <contact_backup>
      <last_name>Felix Morales-Palomo, PhD</last_name>
      <phone>+3492526800</phone>
      <phone_ext>5515</phone_ext>
      <email>felix.morales@uclm.es</email>
    </contact_backup>
    <investigator>
      <last_name>Maria C Muñoz-Turrillas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Mora-Rodriguez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego Mora-Gonzalez, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Morales-Palomo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Alvarez-Jimenez, RD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan F Ortega, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Moreno-Navarrete, J. M., M. Moreno, J. Puig, G. Blasco, F. Ortega, G. Xifra, W. Ricart and J. M. Fernandez-Real (2017).</citation>
  </reference>
  <reference>
    <citation>Van Pelt DW, Newsom SA, Schenk S, Horowitz JF. Relatively low endogenous fatty acid mobilization and uptake helps preserve insulin sensitivity in obese women. Int J Obes (Lond). 2015 Jan;39(1):149-55. doi: 10.1038/ijo.2014.70. Epub 2014 May 2.</citation>
    <PMID>24785103</PMID>
  </reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Castilla-La Mancha</investigator_affiliation>
    <investigator_full_name>Ricardo Mora</investigator_full_name>
    <investigator_title>Director of Exercise Physiology Laboratory</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>data will be shared upon reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

